Anavex Life Sciences Corp.: completes two pharmacology studies

What happened

• On Oct 20, 2026, Anavex Life Sciences Corp. issued a press release providing an update on the clinical development of blarcamesine (ANAVEX®2-73), including the completion of the clinical conduct of two pharmacology studies: an ADME (absorption, distribution, metabolism and excretion) study and a DDI (drug-drug interaction) study.
• The company filed the press release as part of the Current Report on Form 8-K.

Key details

• Date of press release and filing: Oct 20, 2026.
• Drug referenced: blarcamesine (ANAVEX®2-73).
• Studies completed: 1 ADME study; 1 DDI study.
• Item reported on the Form 8-K: Item 8.01 (other events).

Why it may matter

• The filing reports an Item 8.01 other events disclosure, which covers the company issuing a press release about the clinical development of blarcamesine and completing the clinical conduct of two pharmacology studies.
• This filing does not show why the insider traded or why the company acted.